BioNexus Gene Lab Corp. (NASDAQ:BGLC – Get Free Report) saw a large increase in short interest in August. As of August 31st, there was short interest totalling 110,600 shares, an increase of 7.3% from the August 15th total of 103,100 shares. Based on an average daily volume of 136,800 shares, the short-interest ratio is presently 0.8 days. Currently, 1.4% of the shares of the stock are short sold.
BioNexus Gene Lab Trading Up 1.4 %
Shares of NASDAQ:BGLC opened at $0.45 on Tuesday. BioNexus Gene Lab has a 52-week low of $0.31 and a 52-week high of $3.39. The company has a fifty day moving average of $0.45 and a 200-day moving average of $0.55.
BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The company reported $0.01 EPS for the quarter. BioNexus Gene Lab had a negative return on equity of 23.07% and a negative net margin of 24.01%. The firm had revenue of $1.98 million for the quarter.
Hedge Funds Weigh In On BioNexus Gene Lab
About BioNexus Gene Lab
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.
See Also
- Five stocks we like better than BioNexus Gene Lab
- How to Effectively Use the MarketBeat Ratings Screener
- Lock In Gains: Apple Stock Could Rally 30% Before the Holidays
- The Significance of Brokerage Rankings in Stock Selection
- How to Apply Trading Volume Analysis to Stock Trading
- Consumer Discretionary Stocks Explained
- Market Got It Wrong—Why Progress Software Deserves a Second Look
Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.